OncoSil Medical Limited / Fundamentals

    Income statement

    Net revenue
    €926.15K
    Cost of goods sold
    €7.65M
    Gross profit
    -€7.02M
    SG&A expenses
    €6.30M
    R&D expenses
    €3.07M
    EBITDA
    -€14.37M
    D&A
    €101.88K
    EBIT
    -€14.52M
    Interest expenses
    €5.24K
    EBT
    -€14.78M
    Tax expenses
    -€1.17M
    Net income
    -€13.88M

    Cash flow statement

    Net deferred tax
    €36.79K
    Non-cash items
    €445.90K
    Changes in working capital
    -€236.44K
    Operating cash flow
    -€12.80M
    Capex
    €147.28K
    Other investing cash flow
    €0.00
    Net investing cash flow
    €5.11M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €9.04M
    Debt repayment
    -€105.11K
    Other financing cash flow
    €14.57M
    Net financing cash flow
    €14.46M
    Foreign exchange effects
    -€5.26M
    Net change in cash
    €4.04M
    Cash at end of period
    €4.74M
    Free cash flow
    -€12.65M

    Balance sheet

    Cash and cash equivalents
    €4.74M
    Cash and short-term investments
    €4.74M
    Total receivables
    €228.32K
    Inventory
    €0.00
    Other current assets
    €1.23M
    Total current assets
    €6.20M
    Property, plant & equipment
    €239.10K
    Goodwill
    €0.00
    Intangible assets
    €0.00
    Long-term investments
    €0.00
    Other non-current assets
    €0.00
    Total non-current assets
    €239.10K
    Total assets
    €6.44M
    Accounts payable
    €1.28M
    Short-term debt
    €18.66K
    Other current liabilities
    €328.02K
    Total current liabilities
    €1.63M
    Long-term debt
    €21.03K
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €0.00
    Total non-current liabilities
    €21.03K
    Total liabilities
    €1.65M
    Common stock
    €53.18M
    Retained earnings
    -€55.72M
    Other equity
    €7.34M
    Total equity
    €4.79M
    Total liabilities and shareholders' equity
    €6.44M

    Company information

    Market capitalization
    €9.24M
    Employees
    2
    Enterprise Value
    €5.42M

    Company ratios

    Gross margin
    -758.3% Much worse than peer group: 319.2%
    EBITDA margin
    -1,551.1% Much better than peer group: -15,258.1%
    EBIT margin
    -1,568.0% Much better than peer group: -18,090.2%
    EBT margin
    -1,596.3% Much better than peer group: -3,115.3%
    Net margin
    -1,498.3% Much better than peer group: -4,108.9%
    ROE
    -289.4% Much worse than peer group: -136.6%
    ROA
    -215.4% Much worse than peer group: -115.3%
    Asset turnover
    14.4% Even with peer group: 16.7%
    FCF margin
    -1,397.9% Much worse than peer group: -802.5%
    FCF yield
    -140.1%
    Efficiency ratio
    1,651.1%
    Net sales per employee
    €463.08K
    Net income per employee
    -€6.94M

    Notifications